[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transbronchial-cryobiopsy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transbronchial-cryobiopsy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100535427","application-of-transbronchial-cryobiopsy-in-the-diagnosis-of-progressive-pulmonary-fibrosis-100535427",false,"NCT06251687","Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis","Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis：a Multicenter Prospective Study","Inclusion Criteria:\n\nPatients with PPF, ≥18 years of age, unclassified ILD, HRCT ≤3 months, forced vital capacity (FVC)≥50% predicted value, pulmonary carbon monoxide diffusion (DLCO)≥35% predicted value, echocardiography ≤12 months, estimated pulmonary systolic blood pressure ≤40 mmHg, Body mass index (BMI)≤35 kg\u002Fm2.\n\nExclusion Criteria:\n\nPatients with platelet counts below 50,000×109\u002FL or International Normalized ratio of prothrombin time (INR) above 1.5 are not eligible for TBLC","ALL","18 Years","80 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical study is to learn about the diagnostic effectiveness, safety, and influencing factors of transbronchial cryobiopsy（TBLC）in progressive pulmonary fibrosis. The main question it aims to answer are: • Determine the prognosis, health economics, and therapeutic strategy changes of patients with TBLC retrograde malleable pulmonary fibrosis. Participants will be randomly divided into two groups, and received TBLB or TBLC.",[27,28],"Pulmonary Fibrosis","Transbronchial Cryobiopsy","RECRUITING","2025-02-07",{"date":32,"type":33},"2025-02-10","ACTUAL",{"date":35,"type":33},"2024-02-01",{"date":37,"type":21},"2026-12-31",{"name":39,"class":40},"China-Japan Friendship Hospital","OTHER"]